Results 11 to 20 of about 290,432 (308)
Structure and interactions of the human programmed cell death 1 receptor. [PDF]
J Biol Chem, 2013 PD-1, a receptor expressed by T cells, B cells, and monocytes, is a potent regulator of immune responses and a promising therapeutic target. The structure and interactions of human PD-1 are, however, incompletely characterized. We present the solution nuclear magnetic resonance (NMR)-based structure of the human PD-1 extracellular region and detailed ...
Cheng X +18 more
europepmc +4 more sources
Correlation of E-cadherin, vimentin, CD206, programmed cell death receptor 1, and programmed cell death ligand 1 expressions with clinicopathological factors and prognosis in oral squamous cell carcinoma [PDF]
Journal of International Medical ResearchObjective Oral squamous cell carcinoma is the most common malignant tumor occurring in the head and neck region. Current treatment principles are based on radical surgery, supplemented by radiotherapy and chemotherapy.
Zheng-Yi Lai +5 more
doaj +2 more sources
Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells. [PDF]
Int J Mol Sci, 2019 Programmed cell death-1 (PD-1) is a cell surface receptor that dampens adaptive immune responses. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. This results in the inhibition of T cell proliferation, differentiation, cytokine secretion, and cytolytic function.
Mallett G, Laurence A, Amarnath S.
europepmc +5 more sources
An update on immunotherapy with PD-1 and PD-L1 blockade [PDF]
Yeungnam University Journal of Medicine, 2021 Cancer is the leading cause of death and is on the rise worldwide. Until 2010, the development of targeted treatment was mainly focused on the growth mechanisms of cancer.
Sung Ae Koh
doaj +1 more source
The Role of Programmed Cell Death Receptor 1 in Lung Cancer [PDF]
In Vivo, 2022 Lung cancer is the most common cancer worldwide. Cancer immunotherapy is the activation of the immune system against cancer. The latest method of immunotherapy involves immune checkpoint inhibitors. Increased levels of programmed death ligand 1 (PD-L1) expression were observed on non-small-cell lung cancer.
Dumitru Cristinel, Badiu +5 more
openaire +2 more sources
Brain Sciences, 2022 Purpose: This study aims to investigate PD-1/PD-L1 expression patterns in paired primary and recurrent gliomas. Methods: From January 2008 to December 2014, 42 patients who underwent surgical resections of primary and recurrent gliomas were ...
Wei Yu +5 more
doaj +1 more source
Frontiers in Oncology, 2021 BackgroundProgrammed death 1/ligand 1 (PD-1/L1) inhibitors have acceptable antitumor activity in patients with platinum-resistant urothelial cancer (UC).
Zaishang Li +20 more
doaj +1 more source
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
BMC Cancer, 2022 Background Mantle cell lymphoma (MCL) has remained incurable in most patients. The expression of PD-L1 as a prognostic and predictive marker has not been fully evaluated in MCL.
Fereshteh Ameli +3 more
doaj +1 more source
Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression
Tzu Chi Medical Journal, 2022 Melanocytic nevi, dysplastic nevi, and melanoma are all derived from the pigment-producing cells, namely melanocytes. Concerning the clinical spectrum, cutaneous melanoma is the most aggressive skin cancer with a low survival rate, while nevi are the ...
Wei-Wen Sung, Chung-Hsing Chang
doaj +1 more source
口腔疾病防治, 2021 Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand ...
ZENG Fei +6 more
doaj +1 more source